Does the infant need to receive nirsevimab if the mother has been vaccinated with a respiratory syncytial virus (RSV) vaccine?

Does Baby Need Nirsevimab if Mother Got RSV Vaccine?

Most infants do NOT need nirsevimab if the mother received the RSV vaccine ≥14 days before birth and the infant was born at ≥34 weeks gestational age. 111

When Nirsevimab IS NOT Needed

The infant is protected by maternal antibodies and does not require nirsevimab if ALL of the following criteria are met:

• Mother received RSVpreF vaccine ≥14 days before delivery
• Infant born at ≥34 weeks gestational age
• Infant is otherwise healthy without high-risk conditions

This is because at least 14 days are required for maternal antibody development and transplacental transfer, and the earliest an infant could be considered protected is at 34 gestational weeks (if mother vaccinated at 32 weeks) 11.

When Nirsevimab IS Recommended Despite Maternal Vaccination

Give nirsevimab to infants born to vaccinated mothers in these situations:

Timing Issues:

• Infant born <14 days after maternal vaccination 111
• Infant born at <34 weeks gestational age (regardless of timing of maternal vaccine) 11

Maternal Factors Affecting Antibody Transfer:

• Mother has immunocompromising conditions (may not mount adequate immune response) 11
• Mother has conditions affecting transplacental transfer (e.g., HIV infection) 11

Infant High-Risk Conditions:

• Hemodynamically significant congenital heart disease 11
• Chronic lung disease of prematurity 11
• Intensive care admission requiring oxygen at hospital discharge 11
• Infants who underwent cardiopulmonary bypass or ECMO (may have lost maternal antibodies) 11

Unknown Vaccination Status:

• Mother's receipt of RSVpreF vaccine is unknown 11
• Mother did not receive RSVpreF vaccine 11

Special Populations

Infants 8-19 months entering their second RSV season: These children at increased risk for severe RSV disease should receive nirsevimab regardless of maternal RSVpreF vaccination 111.

Clinical Judgment Considerations

While the guideline states nirsevimab is "not needed for most infants" whose mothers were vaccinated appropriately, it may be considered in rare circumstances based on clinical judgment when the potential incremental benefit is warranted 11. However, this should be the exception, not the rule.

Common Pitfalls to Avoid

1. Don't assume protection if timing is unclear - Verify the exact date of maternal vaccination relative to delivery
2. Don't forget gestational age cutoff - Even with proper vaccine timing, infants <34 weeks need nirsevimab
3. Don't overlook maternal immunocompromise - Ask about HIV, immunosuppressive medications, or other conditions affecting immune response
4. Don't skip nirsevimab for high-risk infants - Cardiac and pulmonary conditions warrant nirsevimab even with maternal vaccination

Recent real-world data from France suggests nirsevimab may provide superior protection compared to maternal vaccination alone, with a 26% lower risk of RSV hospitalization 2, though both strategies remain officially recommended as equivalent options.